In conclusion, although our data should be confirmed in experimental models and clinical trials, they suggest that the study of the HLA-B −21M/T genotype could contribute to optimizing immunotherapy in patients with bladder cancer. This evidence concerns the gene HLA-B and urinary bladder carcinoma.